Coya Therapeutics announces results from COYA 303 in vivo animal study

Coya Therapeutics (COYA) announced results of an in vivo animal study designed to evaluate the effects of COYA 303 in a well-characterized in vivo lipopolysaccharide preclinical mouse model of systemic and neurologic inflammation. Results from this completed study confirmed the interim findings previously reported by the company. In this animal model, mice received daily injections of LPS for five days to induce a moderate but sustained inflammatory response representative of chronic inflammation seen in neurodegenerative disease. Animals were treated with daily injections of COYA 303 for four days, starting a day after initiation of LPS injections. The study control groups included the individual components of COYA 303, vehicle-only, and LPS-only treated animals. Coya intends to publish a full dataset which the company believes demonstrates that COYA 303 significantly modulates multiple systemic and central nervous system immune parameters and shifts monocytes from a pro-inflammatory to an anti-inflammatory phenotype. Moreover, the company believes COYA 303 has significant effects on multiple Treg-associated activation and functional markers, indicating enhanced Treg stability and suppressive capacity.